Gastrointestinal Bleed | Upper & Lower GI Bleeding Management

Definition & Classification

GI bleeding refers to any hemorrhage originating from the gastrointestinal tract, from the oropharynx to the rectum. It is classified anatomically based on the Ligament of Treitz — the suspensory ligament of the duodenum at the duodenojejunal junction.

Upper GI Bleed (UGIB)

Proximal to the Ligament of Treitz. Accounts for ~80% of all GI bleeds. Mortality: 6–10%.

▸ Peptic Ulcer Disease (35–50%)
▸ Variceal Bleeding (10–20%)
▸ Mallory-Weiss Tear (5–10%)
▸ Erosive Gastritis / Esophagitis
▸ Dieulafoy Lesion
▸ Angiodysplasia / AVM
▸ Aortoenteric Fistula (rare, catastrophic)
▸ Upper GI Malignancy

Lower GI Bleed (LGIB)

Distal to the Ligament of Treitz. Accounts for ~20%. Generally lower mortality but can be massive.

▸ Diverticular Bleed (30–40%)
▸ Angiodysplasia (5–20%)
▸ Colorectal Neoplasm / Polyps
▸ Hemorrhoids (most common overall)
▸ Inflammatory Bowel Disease
▸ Ischemic Colitis
▸ Meckel's Diverticulum (young)
▸ Rectal Ulcer / Radiation Proctitis

Clinical Presentation — What You See at the Bedside

Feature	UGIB	LGIB
Hematemesis	Present (coffee-ground or frank blood)	Absent
Melena	Very common (black tarry stool)	Rare (proximal colon only)
Hematochezia	Massive UGIB only (10–15%)	Classic presentation
BUN:Creatinine	>30:1 (blood protein absorbed)	Normal
NG Aspirate	Bloody or coffee-ground	Clear / bilious
Hemodynamics	Often unstable early	Usually stable initially

⚡ Clinical Pearl from ICU Experience

A patient with hematochezia + hemodynamic instability — always rule out massive UGIB first. Up to 15% of apparent LGIB is actually a brisk upper source. Start with upper endoscopy (EGD) before colonoscopy in such cases.

Initial Assessment — The First 15 Minutes

Airway

Massive hematemesis → consider intubation for airway protection, especially in encephalopathic cirrhotics. GCS < 8 = intubate.

Breathing

High-flow O₂. Watch for aspiration. SpO₂ monitoring. Tachypnea may indicate acidosis from hemorrhagic shock.

Circulation — This Is Where You Save Lives

Two large-bore IV access (16G or 18G) antecubital. Immediate type & crossmatch. NS/RL bolus. Activate massive transfusion protocol if hemodynamically unstable. Target MAP ≥ 65 mmHg. In variceal bleed, aim for conservative resuscitation — SBP ~90–100 mmHg to avoid rebleed.

Disability

Assess GCS. Hepatic encephalopathy in cirrhotics. Syncope and confusion suggest significant hypovolemia (>30% blood volume loss).

Exposure & Examination

Stigmata of chronic liver disease (spider nevi, caput medusae, palmar erythema). DRE — melena vs. fresh blood. Abdominal exam for tenderness, distension, peritonism. Skin: pallor, capillary refill >3s, cool peripheries.

Urgent Investigations — Order Immediately

HEMATOLOGY

• CBC with differential (Hb may be normal acutely — hemodilution takes 24–72h)
• Blood group, Type & Crossmatch (at least 4 units PRBC)
• PT/INR, aPTT (coagulopathy workup)
• Platelet count
• Reticulocyte count

BIOCHEMISTRY

• BUN/Creatinine (BUN:Cr >30 = UGIB)
• LFT (albumin, bilirubin — liver disease?)
• Serum Lactate (perfusion marker)
• Electrolytes (K⁺ shifts in renal failure)
• ABG / VBG (acidosis, base deficit)

SPECIAL

• ECG (demand ischemia in elderly)
• CXR (aspiration, perforation)
• Fibrinogen (DIC screen)
• Ammonia (if hepatic encephalopathy)

BEDSIDE

• Nasogastric aspirate (if doubt about source)
• Digital rectal exam
• Point-of-care ultrasound (IVC collapsibility)
• Shock Index (HR/SBP) — >1.0 = significant bleed

Upper GI Bleed — Detailed Etiology & Management

Pathophysiology: Mucosal erosion through muscularis mucosae, exposing submucosal vessels. H. pylori (60–70%) and NSAIDs (20–25%) are the two dominant etiologies. Dual antiplatelet therapy, corticosteroids, SSRIs, and physiological stress (Curling's/Cushing's ulcers) contribute.

Forrest Classification (endoscopic — dictates management):

Class	Description	Rebleed Risk
Ia	Spurting hemorrhage	90%
Ib	Oozing hemorrhage	50%
IIa	Visible vessel (non-bleeding)	43%
IIb	Adherent clot	22%
IIc	Flat pigmented spot	10%
III	Clean base ulcer	5%

Endoscopic Therapy (Forrest Ia, Ib, IIa):

• Dual therapy recommended: Epinephrine injection (1:10,000) + thermal coagulation (bipolar/heater probe) or hemoclips
• Epinephrine monotherapy is insufficient — always combine with a second modality
• Hemospray (TC-325) for diffuse oozing or as a bridge
• Over-the-scope clips (OTSC) for large/deep ulcers with refractory bleeding

Post-Endoscopic Care:

• IV PPI: Pantoprazole 80mg bolus → 8mg/hr infusion × 72h (high-risk stigmata)
• H. pylori testing (CLO test, histology, stool antigen) — eradicate with triple/quadruple therapy
• Repeat endoscopy at 6–8 weeks for gastric ulcers (malignancy rule-out)
• Discontinue offending agents (NSAIDs, anticoagulants if safe)

🩺 Clinical Experience Note

In CKD patients on hemodialysis, PUD is extremely common due to uremic gastropathy + heparin use during dialysis. I routinely maintain PPI prophylaxis and use citrate-based anticoagulation when possible. Platelet dysfunction in uremia compounds the bleeding risk — DDAVP 0.3μg/kg can improve platelet function acutely.

Pathophysiology: Portal hypertension (HVPG >12 mmHg) → portosystemic collaterals → esophageal/gastric varices. Risk of bleed is proportional to variceal size, HVPG, and Child-Pugh score. 6-week mortality: 15–20%.

Immediate Management — The Golden Hour:

Step 1: Resuscitation (Conservative)

Target Hb 7–8 g/dL. Over-transfusion increases portal pressure and rebleeding risk. Use PRBC with restrictive strategy. Correct INR with FFP only if actively bleeding and INR >1.5. Platelet transfusion if <50,000/μL.

Step 2: Vasoactive Drugs — Start BEFORE Endoscopy

Octreotide 50μg IV bolus → 50μg/hr infusion × 3–5 days
OR Terlipressin 2mg IV q4h → taper to 1mg q4h after bleeding controlled
These reduce splanchnic blood flow and portal pressure. Start immediately on suspicion — do not wait for endoscopy.

Step 3: Antibiotic Prophylaxis — Mandatory

Ceftriaxone 1g IV daily × 7 days (preferred in advanced cirrhosis)
OR Norfloxacin 400mg PO BID. Reduces bacterial translocation, SBP, and mortality by 20%.

Step 4: Emergency Endoscopy (within 12h)

Esophageal varices: Endoscopic Variceal Ligation (EVL/banding) — first-line. 6 bands per session.
Gastric varices (GOV2, IGV1): Cyanoacrylate (glue) injection — EVL is ineffective for fundal varices.
If endoscopy fails: Balloon tamponade (Sengstaken-Blakemore tube) as bridge to TIPS — max 24h, high complication rate.

Step 5: Salvage — TIPS

Transjugular Intrahepatic Portosystemic Shunt. For refractory/recurrent variceal bleeding despite optimal endoscopic + medical therapy. Early TIPS (within 72h) recommended in Child-Pugh C (10–13) or Child-Pugh B with active bleeding at endoscopy.

Secondary Prophylaxis: EVL q2–4 weeks until obliteration + Non-selective beta-blocker (Propranolol 20–40mg BID or Carvedilol 6.25–12.5mg daily). Target HR reduction 25% or resting HR 55–60 bpm.

🩺 Nephrology Crossover — Hepatorenal Syndrome

Always watch for HRS in variceal bleeders. The combination of hypovolemia + splanchnic vasodilation triggers AKI. Terlipressin + albumin is the treatment of choice for HRS-AKI. In my practice, I've seen patients on HD with cirrhosis where timing of dialysis around variceal banding is critical — we delay HD 24h post-banding to avoid heparin-related rebleed.

Mallory-Weiss Tear: Longitudinal mucosal laceration at GEJ from forceful retching/vomiting. Common in alcoholics, bulimia, severe coughing. 90% stop spontaneously. Endoscopic treatment (clips, epinephrine) for persistent bleeding.

Erosive Esophagitis: Severe GERD, pill esophagitis (bisphosphonates, doxycycline, KCl, iron), infectious (CMV, HSV, Candida in immunocompromised). PPI therapy. Endoscopic hemostasis if actively bleeding.

Dieulafoy Lesion: Aberrant large-caliber submucosal artery (1–3mm) that erodes through mucosa without surrounding ulceration. Can cause massive, intermittent bleeding. Often missed on first endoscopy. Hemoclips or thermal therapy. Can occur anywhere in GI tract — most common in proximal stomach along lesser curvature.

Angiodysplasia (AVM): Dilated, tortuous submucosal vessels. More common in elderly, CKD patients (especially on dialysis), aortic stenosis (Heyde syndrome), and von Willebrand disease. Argon plasma coagulation (APC) is treatment of choice. Recurrence is high.

🩺 Nephrology Note — Angiodysplasia in CKD

GI angiodysplasia is disproportionately common in my dialysis population. Uremic platelet dysfunction (qualitative) + heparin use + angiodysplasia = recurrent GI bleeds. Management: DDAVP, conjugated estrogens (0.6mg/kg/day IV × 5 days for chronic recurrent AVM bleeds), optimized dialysis adequacy, and iron replacement for chronic iron deficiency.

Glasgow-Blatchford Score (GBS)

Pre-endoscopic risk stratification for UGIB. Used to identify patients who need intervention vs. safe for outpatient management. GBS = 0 → safe for outpatient management (can avoid admission). GBS ≥ 6 = high risk.

BUN (mg/dL)

Hemoglobin (g/dL) — Male

Systolic BP (mmHg)

Heart Rate

Melena

Syncope

Hepatic Disease

Heart Failure

Glasgow-Blatchford Score

Low Risk

Consider outpatient management

Rockall Score (Post-Endoscopy)

Post-endoscopic mortality risk. Combines clinical + endoscopic data. Score ≤ 2: excellent prognosis. Score ≥ 8: high mortality (>40%).

Variable	0	1	2	3
Age	<60	60–79	≥80	—
Shock	None	HR>100	SBP<100	—
Comorbidity	None	—	CCF, IHD, major	Renal/liver failure, malignancy
Diagnosis	MW, no lesion	All other	GI malignancy	—
Stigmata of hemorrhage	None / dark spot	—	Blood, adherent clot, visible vessel	—

AIMS65 Score

Predicts inpatient mortality in UGIB. Simple, bedside. Score ≥ 2 = high risk.

Albumin <3.0

INR >1.5

Mental status altered

SBP ≤90

Age ≥65

Resuscitation & Transfusion Strategy

Hemorrhagic Shock Classification (ATLS)

Parameter	Class I	Class II	Class III	Class IV
Blood Loss	<750 mL (<15%)	750–1500 (15–30%)	1500–2000 (30–40%)	>2000 (>40%)
Heart Rate	<100	100–120	120–140	>140
Blood Pressure	Normal	Normal	Decreased	Very low
Urine Output	>30 mL/h	20–30	5–15	Negligible
Mental Status	Normal	Anxious	Confused	Lethargic

Transfusion Targets

Restrictive Strategy (Preferred)

• PRBC: Transfuse when Hb <7 g/dL (target 7–9)
• Variceal bleed: Hb target 7–8 g/dL (strict)
• IHD / ACS: Hb target 8–10 g/dL (liberal)
• Over-transfusion in cirrhotics increases portal pressure and rebleeding

Component Therapy

• FFP: INR >1.5 with active bleeding
• Platelets: <50,000/μL with active bleed
• Cryoprecipitate: Fibrinogen <100 mg/dL
• Massive Transfusion Protocol: PRBC:FFP:Platelets = 1:1:1

🩺 ICU Experience: Fluid Resuscitation in GI Bleed + AKI

As a nephrologist-intensivist, I frequently manage GI bleed in CKD/ESRD patients. Key considerations: (1) These patients are often fluid-overloaded at baseline — avoid NS boluses unless truly hypovolemic; use PRBC as the volume expander. (2) Uremic coagulopathy: DDAVP 0.3μg/kg IV pre-procedure, conjugated estrogens for recurrent bleeds. (3) If patient is on dialysis, coordinate timing — avoid heparin; use citrate anticoagulation. (4) Metabolic acidosis + hyperkalemia can be severe in hemorrhagic shock + CKD — may need emergency dialysis. (5) Monitor lactate clearance as resuscitation endpoint.

Pharmacological Management — Complete Drug Reference

Proton Pump Inhibitors (PPI)

Pantoprazole / Esomeprazole:

HIGH RISK (Forrest Ia–IIb): 80mg IV bolus → 8mg/hr continuous infusion × 72 hours → then 40mg PO BID

LOW RISK (Forrest IIc–III): 40mg IV BID → 40mg PO daily

Mechanism: Raises intragastric pH >6 → stabilizes clot. Continuous infusion is superior to intermittent bolus for high-risk stigmata.

CKD adjustment: No dose adjustment needed. PPI-associated AIN is a concern in nephrology — monitor Cr in long-term users.

Vasoactive Agents (Variceal Bleed)

Octreotide (Somatostatin analog)

50μg IV bolus → 50μg/hr infusion × 3–5 days

Reduces splanchnic blood flow. Fewer side effects than vasopressin. Can be used in CKD without adjustment.

Terlipressin (V1 agonist)

2mg IV q4h → taper 1mg q4h after control

Most effective vasoactive agent. Also used for HRS. Caution: coronary/mesenteric vasoconstriction — avoid in IHD. Preferred in HRS-AKI.

Antibiotic Prophylaxis (Variceal Bleed)

Ceftriaxone 1g IV daily × 7 days (preferred in Child-Pugh B/C)
Alternative: Norfloxacin 400mg PO BID × 7 days

Reduces bacterial translocation, SBP, rebleeding, and mortality. This is one of the most impactful interventions in variceal bleed — NNT = 4 to prevent one infection.

Other Important Agents

Erythromycin (prokinetic): 250mg IV 30–90 min before endoscopy. Promotes gastric emptying, improves endoscopic visualization, reduces need for repeat EGD. Evidence-based; recommended by ACG.

Tranexamic Acid (TXA): 1g IV over 10 min. The HALT-IT trial (2020) showed NO benefit and increased VTE risk in GI bleed. Not recommended routinely. Consider only in massive hemorrhage with documented hyperfibrinolysis.

DDAVP (Desmopressin): 0.3μg/kg IV over 30 min. For uremic platelet dysfunction in CKD/ESRD. Releases vWF multimers from endothelium. Effect lasts ~6h. Tachyphylaxis after 2–3 doses.

Conjugated Estrogens: 0.6mg/kg/day IV × 5 days. For chronic/recurrent GI bleeding in CKD, especially angiodysplasia. Effect lasts 2 weeks. Mechanism: reduces bleeding time by improving platelet-endothelial interaction.

Vitamin K: 10mg IV slow push. For warfarin reversal. Takes 6–12h for full effect. Use FFP/4-factor PCC for urgent reversal.

Anticoagulant / Antiplatelet Reversal

Drug	Reversal Agent	Notes
Warfarin	Vitamin K + 4F-PCC (Kcentra) or FFP	PCC preferred (rapid, lower volume)
Dabigatran	Idarucizumab (Praxbind) 5g IV	Specific reversal. HD can remove dabigatran
Rivaroxaban/Apixaban	Andexanet alfa or 4F-PCC	NOT dialyzable (highly protein bound)
Heparin (UFH)	Protamine sulfate	1mg per 100 units heparin (last 2–3h)
Aspirin / Clopidogrel	Platelet transfusion (if life-threatening)	Hold clopidogrel. Aspirin: consider continuing if cardiac stent <30d

Gastrointestinal Bleed
Diagnosis & Management